Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

LuTHy: a double-readout bioluminescence-based two-hybrid technology for quantitative mapping of protein-protein interactions in mammalian cells.

Trepte P, Kruse S, Kostova S, Hoffmann S, Buntru A, Tempelmeier A, Secker C, Diez L, Schulz A, Klockmeier K, Zenkner M, Golusik S, Rau K, Schnoegl S, Garner CC, Wanker EE.

Mol Syst Biol. 2018 Jul 11;14(7):e8071. doi: 10.15252/msb.20178071.

2.

Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.

Rau KM, Ou-Yang F, Chao TC, Kuo YL, Cheng TF, Chao TY, Chen DR, Tzeng YD, Wang BW, Liu CY, Hu MH, Lu YC, Ou WJ, Kuo CH, Chuang CH, Kan JY, Chen FM, Hou MF.

Breast Cancer Res Treat. 2018 Aug;170(3):583-591. doi: 10.1007/s10549-018-4778-y. Epub 2018 Apr 5.

3.

Patient-clinician relationship seems to affect adherence to analgesic use in cancer patients: a cross sectional study in a Taiwanese population.

Chou PL, Rau KM, Yu TW, Huang TL, Sun JL, Wang SY, Lin CC.

Int J Qual Health Care. 2017 Nov 1;29(7):935-940. doi: 10.1093/intqhc/mzx134.

PMID:
29087488
4.

Cancer-related pain: a nationwide survey of patients' treatment modification and satisfaction in Taiwan.

Rau KM, Chen JS, Wu HB, Lin SF, Huang ML, Tai CJ, Hwang WL, Lu YC, Wang CC, Kuen Hsieh R.

Jpn J Clin Oncol. 2017 Nov 1;47(11):1060-1065. doi: 10.1093/jjco/hyx124.

5.

High expression of endoglin in primary breast cancer may predict response to neoadjuvant chemotherapy.

Rau KM, Su YL, Li SH, Hsieh MC, Wu SC, Chou FF, Chiu TJ, Chen YH, Liu CT.

Mol Med Rep. 2017 Nov;16(5):7185-7190. doi: 10.3892/mmr.2017.7555. Epub 2017 Sep 20.

6.

Making the Message Clear: Concepts for mRNA Imaging.

Rau K, Rentmeister A.

ACS Cent Sci. 2017 Jul 26;3(7):701-707. doi: 10.1021/acscentsci.7b00251. Epub 2017 Jul 6. Review.

7.

Gender Difference in Cancer Patients' Adherence to Analgesics and Related Outcomes of Pain Management.

Chou PL, Fang SY, Sun JL, Rau KM, Lee BO.

Cancer Nurs. 2017 Jul 27. doi: 10.1097/NCC.0000000000000532. [Epub ahead of print]

PMID:
28753193
8.

Impact of Undertreatment of Cancer Pain With Analgesic Drugs on Patient Outcomes: A Nationwide Survey of Outpatient Cancer Patient Care in Taiwan.

Shen WC, Chen JS, Shao YY, Lee KD, Chiou TJ, Sung YC, Rau KM, Yen CJ, Liao YM, Liu TC, Wu MF, Lee MY, Yu MS, Hwang WL, Lai PY, Chang CS, Chou WC, Hsieh RK.

J Pain Symptom Manage. 2017 Jul;54(1):55-65.e1. doi: 10.1016/j.jpainsymman.2017.02.018. Epub 2017 May 4.

PMID:
28479410
9.

The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis.

Kuo YH, Wu IP, Wang JH, Hung CH, Rau KM, Chen CH, Kee KM, Hu TH, Lu SN.

Invest New Drugs. 2018 Apr;36(2):307-314. doi: 10.1007/s10637-017-0468-6. Epub 2017 May 2.

PMID:
28466374
10.

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer.

Adiwijaya BS, Kim J, Lang I, Csõszi T, Cubillo A, Chen JS, Wong M, Park JO, Kim JS, Rau KM, Melichar B, Gallego JB, Fitzgerald J, Belanger B, Molnar I, Ma WW.

Clin Pharmacol Ther. 2017 Dec;102(6):997-1005. doi: 10.1002/cpt.720. Epub 2017 Jun 5.

11.

Cutaneous TRPM8-expressing sensory afferents are a small population of neurons with unique firing properties.

Jankowski MP, Rau KK, Koerber HR.

Physiol Rep. 2017 Apr;5(7). pii: e13234. doi: 10.14814/phy2.13234.

12.

Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.

Kuo YH, Wang JH, Hung CH, Rau KM, Wu IP, Chen CH, Kee KM, Hu TH, Lu SN.

J Gastroenterol Hepatol. 2017 Dec;32(12):1975-1981. doi: 10.1111/jgh.13783.

PMID:
28295594
13.

Defective lipid metabolism associated with mutation in klf-2 and klf-3: important roles of essential dietary salts in fat storage.

Ling J, Brey C, Schilling M, Lateef F, Lopez-Dee ZP, Fernandes K, Thiruchelvam K, Wang Y, Chandel K, Rau K, Parhar R, Al-Mohanna F, Gaugler R, Hashmi S.

Nutr Metab (Lond). 2017 Feb 28;14:22. doi: 10.1186/s12986-017-0172-8. eCollection 2017.

14.

Fragmentation of the CRISPR-Cas Type I-B signature protein Cas8b.

Richter H, Rompf J, Wiegel J, Rau K, Randau L.

Biochim Biophys Acta. 2017 Nov;1861(11 Pt B):2993-3000. doi: 10.1016/j.bbagen.2017.02.026. Epub 2017 Feb 24.

PMID:
28238733
15.

The effects of hospice-shared care for gastric cancer patients.

Huang KS, Wang SH, Chuah SK, Rau KM, Lin YH, Hsieh MC, Shih LH, Chen YH.

PLoS One. 2017 Feb 3;12(2):e0171365. doi: 10.1371/journal.pone.0171365. eCollection 2017.

16.

Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma.

Su YL, Hsieh MC, Chiang PH, Sung MT, Lan J, Luo HL, Huang CC, Huang CH, Tang Y, Rau KM.

PLoS One. 2017 Jan 11;12(1):e0169657. doi: 10.1371/journal.pone.0169657. eCollection 2017.

17.

A Survival Scoring System for Non-Small Cell Lung Cancer Patients with De Novo Bone Metastases.

Chen YM, Fang YT, Lai CH, Rau KM, Huang CH, Chang HC, Chao TY, Tseng CC, Fang WF, Wang CC, Chen YC, Chung YH, Wang YH, Su MC, Liu SF, Huang KT, Chen HC, Chang YC, Chang YP, Lin MC.

PLoS One. 2016 Dec 8;11(12):e0167923. doi: 10.1371/journal.pone.0167923. eCollection 2016.

18.

Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.

Chen YM, Lai CH, Rau KM, Huang CH, Chang HC, Chao TY, Tseng CC, Fang WF, Chung YH, Wang YH, Su MC, Huang KT, Liu SF, Chen HC, Chang YC, Chang YP, Wang CC, Lin MC.

BMC Cancer. 2016 Nov 8;16(1):868.

19.

Quantitative interaction mapping reveals an extended UBX domain in ASPL that disrupts functional p97 hexamers.

Arumughan A, Roske Y, Barth C, Forero LL, Bravo-Rodriguez K, Redel A, Kostova S, McShane E, Opitz R, Faelber K, Rau K, Mielke T, Daumke O, Selbach M, Sanchez-Garcia E, Rocks O, Panáková D, Heinemann U, Wanker EE.

Nat Commun. 2016 Oct 20;7:13047. doi: 10.1038/ncomms13047.

20.

EDA-Fibronectin Originating from Osteoblasts Inhibits the Immune Response against Cancer.

Rossnagl S, Altrock E, Sens C, Kraft S, Rau K, Milsom MD, Giese T, Samstag Y, Nakchbandi IA.

PLoS Biol. 2016 Sep 21;14(9):e1002562. doi: 10.1371/journal.pbio.1002562. eCollection 2016 Sep.

21.

A preliminary randomised controlled study of short-term Antrodia cinnamomea treatment combined with chemotherapy for patients with advanced cancer.

Tsai MY, Hung YC, Chen YH, Chen YH, Huang YC, Kao CW, Su YL, Chiu HH, Rau KM.

BMC Complement Altern Med. 2016 Aug 26;16(1):322. doi: 10.1186/s12906-016-1312-9.

22.

Truth telling in Taiwanese cancer care: patients' and families' preferences and their experiences of doctors' practices.

Tang WR, Hong JH, Rau KM, Wang CH, Juang YY, Lai CH, Fujimori M, Fang CK.

Psychooncology. 2017 Jul;26(7):999-1005. doi: 10.1002/pon.4257. Epub 2016 Sep 13.

PMID:
27539879
23.

An O-Glycosylation of Fibronectin Mediates Hepatic Osteodystrophy Through α4β1 Integrin.

Sens C, Altrock E, Rau K, Klemis V, von Au A, Pettera S, Uebel S, Damm T, Tiwari S, Moser M, Nakchbandi IA.

J Bone Miner Res. 2017 Jan;32(1):70-81. doi: 10.1002/jbmr.2916. Epub 2016 Aug 3.

24.

Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors.

Chen YM, Lai CH, Rau KM, Huang CH, Chang HC, Chao TY, Tseng CC, Fang WF, Chen YC, Chung YH, Wang YH, Su MC, Huang KT, Liu SF, Chen HC, Chang YC, Chang YP, Wang CC, Lin MC.

Lung Cancer. 2016 Aug;98:99-105. doi: 10.1016/j.lungcan.2016.05.020. Epub 2016 May 31.

PMID:
27393514
25.

Deletion of the murine ATP/UTP receptor P2Y2 alters mechanical and thermal response properties in polymodal cutaneous afferents.

Molliver DC, Rau KK, Jankowski MP, Soneji DJ, Baumbauer KM, Koerber HR.

Neuroscience. 2016 Sep 22;332:223-30. doi: 10.1016/j.neuroscience.2016.06.054. Epub 2016 Jul 5.

26.

CRISPR/Cas9: A New Tool for RNA Imaging in Live Cells.

Rau K, Rentmeister A.

Chembiochem. 2016 Sep 15;17(18):1682-4. doi: 10.1002/cbic.201600342. Epub 2016 Jul 22.

PMID:
27320049
27.

Cutaneous tissue damage induces long-lasting nociceptive sensitization and regulation of cellular stress- and nerve injury-associated genes in sensory neurons.

Rau KK, Hill CE, Harrison BJ, Venkat G, Koenig HM, Cook SB, Rabchevsky AG, Taylor BK, Hai T, Petruska JC.

Exp Neurol. 2016 Sep;283(Pt A):413-27. doi: 10.1016/j.expneurol.2016.06.002. Epub 2016 Jun 3.

28.

A Prognostic Model Using Inflammation- and Nutrition-Based Scores in Patients With Metastatic Gastric Adenocarcinoma Treated With Chemotherapy.

Hsieh MC, Wang SH, Chuah SK, Lin YH, Lan J, Rau KM.

Medicine (Baltimore). 2016 Apr;95(17):e3504. doi: 10.1097/MD.0000000000003504.

29.

The Adaptor Protein CD2AP Is a Coordinator of Neurotrophin Signaling-Mediated Axon Arbor Plasticity.

Harrison BJ, Venkat G, Lamb JL, Hutson TH, Drury C, Rau KK, Bunge MB, Mendell LM, Gage FH, Johnson RD, Hill CE, Rouchka EC, Moon LD, Petruska JC.

J Neurosci. 2016 Apr 13;36(15):4259-75. doi: 10.1523/JNEUROSCI.2423-15.2016.

30.

Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis.

Rau KM, Chen HK, Shiu LY, Chao TL, Lo YP, Wang CC, Lin MC, Huang CC.

Int J Mol Sci. 2016 Apr 7;17(4):524. doi: 10.3390/ijms17040524.

31.

Prognostic model to predict survival in patients with metastatic upper tract urothelial carcinoma treated with cisplatin-based chemotherapy.

Hsieh MC, Su YL, Chiang PH, Rau KM, Chen YY, Huang CH.

Int J Urol. 2016 May;23(5):385-9. doi: 10.1111/iju.13067. Epub 2016 Mar 14.

32.

Transcriptional changes in sensory ganglia associated with primary afferent axon collateral sprouting in spared dermatome model.

Harrison BJ, Venkat G, Hutson T, Rau KK, Bunge MB, Mendell LM, Gage FH, Johnson RD, Hill C, Rouchka EC, Moon L, Petruska JC.

Genom Data. 2015 Oct 23;6:249-52. doi: 10.1016/j.gdata.2015.10.005. eCollection 2015 Dec.

33.

Osteopontin Involves Cisplatin Resistance and Poor Prognosis in Oral Squamous Cell Carcinoma.

Luo SD, Chen YJ, Liu CT, Rau KM, Chen YC, Tsai HT, Chen CH, Chiu TJ.

Biomed Res Int. 2015;2015:508587. doi: 10.1155/2015/508587. Epub 2015 Sep 30.

34.

Age-Related Changes of 14-3-3 Isoforms in Midbrain of A53T-SNCA Overexpressing Mice.

Brehm N, Rau K, Kurz A, Gispert S, Auburger G.

J Parkinsons Dis. 2015;5(3):595-604. doi: 10.3233/JPD-150606.

PMID:
26406140
35.

Trousseau's syndrome in a patient with advanced stage gastric cancer.

Chien TL, Rau KM, Chung WJ, Tai WC, Wang SH, Chiu YC, Wu KL, Chou YP, Wu CC, Chen YH, Chuah SK; Gastric Cancer Team.

World J Gastroenterol. 2015 Sep 14;21(34):10049-53. doi: 10.3748/wjg.v21.i34.10049.

36.

Asthma and Risk of Prostate Cancer: A Population-Based Case-Cohort Study in Taiwan.

Su YL, Chou CL, Rau KM, Lee CT.

Medicine (Baltimore). 2015 Sep;94(36):e1371. doi: 10.1097/MD.0000000000001371.

37.

The impact of pain control on physical and psychiatric functions of cancer patients: a nation-wide survey in Taiwan.

Rau KM, Chen JS, Wu HB, Lin SF, Lai MK, Chow JM, Huang ML, Wang CJ, Tai CJ, Hwang WL, Lu YC, Chan CH, Hsieh RK.

Jpn J Clin Oncol. 2015 Nov;45(11):1042-9. doi: 10.1093/jjco/hyv124. Epub 2015 Aug 19.

38.

DULIP: A Dual Luminescence-Based Co-Immunoprecipitation Assay for Interactome Mapping in Mammalian Cells.

Trepte P, Buntru A, Klockmeier K, Willmore L, Arumughan A, Secker C, Zenkner M, Brusendorf L, Rau K, Redel A, Wanker EE.

J Mol Biol. 2015 Oct 23;427(21):3375-88. doi: 10.1016/j.jmb.2015.08.003. Epub 2015 Aug 8.

PMID:
26264872
39.

The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.

Hsieh MC, Chiang PH, Rau KM, Chen YY, Su YL, Huang CH.

Urol Oncol. 2015 Nov;33(11):495.e9-495.e14. doi: 10.1016/j.urolonc.2015.07.001. Epub 2015 Aug 5.

PMID:
26254698
41.

Development and validation of the Chinese Version of Spiritual Interests Related Illness Tool for patients with cancer in Taiwan.

Lin YL, Rau KM, Liu YH, Lin YH, Ying J, Kao CC.

Eur J Oncol Nurs. 2015 Oct;19(5):589-94. doi: 10.1016/j.ejon.2015.03.005. Epub 2015 Apr 14.

PMID:
25882548
42.

The effect of spinal cord injury on the neurochemical properties of vagal sensory neurons.

Herrity AN, Petruska JC, Stirling DP, Rau KK, Hubscher CH.

Am J Physiol Regul Integr Comp Physiol. 2015 Jun 15;308(12):R1021-33. doi: 10.1152/ajpregu.00445.2014. Epub 2015 Apr 8.

43.

Longitudinal study on the impact of physical activity on the symptoms of lung cancer survivors.

Lin YY, Rau KM, Lin CC.

Support Care Cancer. 2015 Dec;23(12):3545-53. doi: 10.1007/s00520-015-2724-7. Epub 2015 Apr 9.

PMID:
25855040
44.

Adding bevacizumab to chemotherapy effectively control radioresistant brain metastases in ALK-positive lung adenocarcinoma.

Su YL, Rau KM.

J Thorac Oncol. 2015 Apr;10(4):e21-2. doi: 10.1097/JTO.0000000000000449. No abstract available.

45.

Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy.

Lu YS, Chen TW, Lin CH, Yeh DC, Tseng LM, Wu PF, Rau KM, Chen BB, Chao TC, Huang SM, Huang CS, Shih TT, Cheng AL; Taiwan Breast Cancer Consortium.

Clin Cancer Res. 2015 Apr 15;21(8):1851-8. doi: 10.1158/1078-0432.CCR-14-2075. Epub 2015 Feb 19.

46.

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.

Chen JS, Hsu C, Chiang NJ, Tsai CS, Tsou HH, Huang SF, Bai LY, Chang IC, Shiah HS, Ho CL, Yen CJ, Lee KD, Chiu CF, Rau KM, Yu MS, Yang Y, Hsieh RK, Chang JY, Shan YS, Chao Y, Chen LT; Taiwan Cooperative Oncology Group.

Ann Oncol. 2015 May;26(5):943-9. doi: 10.1093/annonc/mdv035. Epub 2015 Jan 28.

PMID:
25632066
47.

A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.

Lim HY, Heo J, Choi HJ, Lin CY, Yoon JH, Hsu C, Rau KM, Poon RT, Yeo W, Park JW, Tay MH, Hsieh WS, Kappeler C, Rajagopalan P, Krissel H, Jeffers M, Yen CJ, Tak WY.

Clin Cancer Res. 2014 Dec 1;20(23):5976-85. doi: 10.1158/1078-0432.CCR-13-3445. Epub 2014 Oct 7.

48.

Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.

Qin S, Cheng Y, Liang J, Shen L, Bai Y, Li J, Fan J, Liang L, Zhang Y, Wu G, Rau KM, Yang TS, Jian Z, Liang H, Sun Y.

Oncologist. 2014 Nov;19(11):1169-78. doi: 10.1634/theoncologist.2014-0190. Epub 2014 Sep 15.

49.

EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid.

Yeh DC, Chen DR, Chao TY, Chen SC, Wang HC, Rau KM, Feng YH, Chang YC, Lee KD, Ou-Yang F, Kuo WH, Chang KJ, Lin YC, Tseng LM, Hou MF.

In Vivo. 2014 Sep-Oct;28(5):1001-4.

PMID:
25189922
50.

Post-mastectomy radiotherapy benefits subgroups of breast cancer patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.

Su YL, Li SH, Chen YY, Chen HC, Tang Y, Huang CH, Chou FF, Wu SC, Rau KM.

Radiol Oncol. 2014 Jul 10;48(3):314-22. doi: 10.2478/raon-2013-0085. eCollection 2014 Sep.

Supplemental Content

Support Center